Navigation Links
Measuring RNase Activity A Real-time Kinetic Analysis


The RNaseAlert QC System, when used in conjunction with a fluorometer capable of kinetic analysis, provides a rapid and ultra-sensitive assay for determining RNase A specific activity. The RNaseAlert QC System also detects a variety of other nucleases, including RNase A, T1, RNase I, micrococcal nuclease, S1 nuclease, mung bean nuclease, and Benzonase. In addition to detecting nuclease activity, this kit is useful for standardizing activities of these enzymes.


Sources of RNase

Ribonucleases (RNases) are ubiquitous in the environment, and they are present in relatively high concentrations in many biological materials. For example, the pancreas is rich in RNase (>1 mg RNase/1 g tissue) and is the source for most commercially produced RNase A (and its glycosylated derivative, RNase B).

RNase A is an endonuclease that cleaves 3' of C and U residues. It is commonly used in molecular biology applications such as the removal of contaminating RNA from DNA preparations and ribonuclease protection assays (RPA). Ambion sells an RPA grade RNase A (Cat #2272) that is equivalent to molecular biology grade RNase A from other suppliers, as well as affinity-purified RNase A (Cat #2270 and #2271), which is recommended when the absence of DNase and other nonspecific nuclease activities is essential.


Measuring Specific Activity

Recently, Ambion introduced the RNaseAlert QC System, a quantitative fluorometric high-throughput assay for the detection of contaminating RNases. The assay consists of an oligonucleotide substrate that contains a fluorophore on one end and a quencher on the other. Once cleaved by RNase, the fluor and quencher are separated. When excited with 490 nm light, the fluor emits a bright green signal that can be quantitated with a fluorometer (Figure 1).

Figure 1. Schematic of the RNaseAlert QC System.

Are Your Enzyme Units Uniform?

During routine protein purification some proportion of the enzyme population is inevitably inactivated. Therefore, the proportion of active enzyme is routinely quantitated by measuring the specific activity, the amount of active enzyme per mg of the total protein. In 1950, M. Kunitz developed the first spectrophotometric assay for measuring DNase I activity. The assay was based on the increase in A260 at pH 5.0 and 25C caused by the degradation of a DNA substrate. Kunitz also recognized that the rate of increase of A260 under the proper conditions, is both linear and constant and that the linear rates were proportional to the concentration of the active enzyme.

The Kunitz unit has since become the standard unit of measurement for enzymatic activity. However, the original Kunitz assay was performed under conditions that are not optimal for many enzymes, so most manufacturers have developed their own unit assays. Therefore, it is important to look closely at both the manufacturer's unit definition as well as the assay conditions to determine how an enzyme will function in your specific application.

One Kunitz unit (K) produces a change in A260 of 0.001/min/ml at pH 5.0, 25C or 1 unit hydrolyzes a substrate at a rate constant of K = 1 at pH 5.0, 25C.

Here we report the steady-state kinetic analysis of RNase A activity using the RNaseAlert QC System. RNase A (700 U/mg, 10 ng/ml) was serially diluted and incubated with a large excess of substrate such that the amount of input enzyme was proportional to the rate of the reaction. A baseline was established by monitoring substrate alone in RNaseAlert Buffer. After several minutes, experimental samples containing 0.5 pg, 5.0 pg and 50 pg of RNase A were added. The rate of increase in fluorescence was measured in real-time at 37C in 2 minute increments for 1 hour. Figure 2 shows reaction curves plotted for 3 concentrations of enzyme: 50 pg, 5.0 pg, and 0.5 pg. After enzyme addition, the rate of increase in fluorescence was constant for several minutes. Under these conditions, the reaction is at equilibrium and the rate of increase in fluorescence (the slope of the line) can be used to calculate the initial rate (or velocity) of the reaction. As expected, when initial velocities were compared (see legend, Figure 2), there was a 10-fold difference between each 10-fold serial dilution. These data demonstrate that the dilutions maintain the mathematical proportionality predicted for steady-state kinetic analysis.

Figure 2. Kinetics of RNaseAlert Cleavage by RNase A. Using conditions of substracte excess, the rate of increase in fluorescence (the slope of the line) was used to calculate the initial reaction rates for three concentrations of RNase A. The initial velocities were 0.005 RFU/min, 0.054 RFU/min, and 0.5 RFU/min for 0.5 pg, 5.0 pg and 50 pg Rnase A, respectively.


In the Kunitz assay, the linear rate of increase of A260 is proportional to the concentration of the enzyme in solution. The activity of the enzyme is expressed in terms of the slope of the plotted curve of absorbance versus time. Likewise, when tested with the RNaseAlert QC System, the early, linear phase of the reaction yields an increase in relative fluorescence units (RFU) that is proportional to the concentration of enzyme in solution. Therefore, the RNaseAlert QC System, when used in conjunction with a fluorometer capable of kinetic analysis, provides a rapid and ultra-sensitive assay for quantitative measurements of RNase A activity. Since this assay also detects a variety of other nucleuses (RNase T1, RNase I, micrococcal nuclease, S1 nuclease, mung bean nuclease, and Benzonase), it should also be useful for standardizing their specific activity.


References

  1. Kunitz, M (1950) Crystalline Deoxyribonuclease I. Isolation and general properties, spectrophotometric method for the measurement of desoxyribonuclease activity. J. Gen. Physiol. 33: 349-362.
  2. 2. Crook, E, Mathias, A Rabin, B (1960) Spectrophotometric assay of bovine pancreatic ribonuclease by the use of cytidine 2',3'-phosphate. Biochem. J. 74: 234.


back to top


Ordering Information
Cat# Product Name Size 1966 RNaseAlert QC System 5 x 96 assays 2270 RNase A (Affinity purified) 1 mg/ml 200 g 2271 RNase A (Affinity purified) 1 mg/ml 1 mg 2272 RNase A (RPA grade) 1 mg/ml 1 mg
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Measuring multiple apoptosis parameters with the Agilent 2100 bioanalyzer
2. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
3. Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer
4. Measuring siRNA-mediated knockdown of IL-8 mRNA
5. Protector RNase Inhibitor
6. Protector RNase Inhibitor Enhance the Protection of RNA against Degradation
7. RNase Protection Assay (RPA) Using DIG-Labeled RNA Probes
8. Inducing RNAi with siRNA Cocktails Generated by RNase III
9. Dicer vs. RNase III for Preparation of siRNA Cocktails
10. Combat RNase Contamination in the Lab
11. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Measuring RNase Activity Real time Kinetic Analysis

(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Executive Team, FREMONT, Calif., Sept. 8 ... a novel transdermal,delivery technology, today announced that Gail ... The company also announced several recent,appointments to the ... and president; John M. Vuko, executive vice president ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it ... trial using intravenous,administration of REOLYSIN(R) in combination with ... neck cancers. The Principal,Investigator is Dr. Monica Mita ... The University of Texas Health Science Center at ...
... Md., Sept. 8 Neuralstem Inc., CEO,Richard Garr, will ... Lateral Sclerosis, or Lou Gehrig,s disease) at the 2008 ... at 2:00 CDT. In a,presentation prior to the panel, ... trial and give an update of the Company,s filing ...
Cached Biology Technology:Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 2Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 4Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit 2
(Date:10/15/2014)... 15, 2014 Sandata Technologies, LLC, an ... community-based care, today announced it released a case ... Electronic Visit Verification™ Solution (EVV™)  for Quality Care ... health company founded in 1996 and has five ... The study details the challenges facing ...
(Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
(Date:10/15/2014)... Conn. , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market releases ... MarketSite in Times Square on Monday October 13 th . ... CTO David Tunnel and angel investor Mr. Chad ... Pereira , CEO of NXT-ID thanked his investors and employees "for ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... Access to Research Careers) Program has announced the travel ... of Chicanos and Native Americans in Science (SACNAS) annual ... These awards are meant to promote the entry of ... mainstream of the basic science community and to encourage ...
... Fox Foundation for Parkinson,s Research and Shake It Up ... Sydney,s Garvan Institute of Medical Research to look at ... Long non-coding RNAs are complex molecules, produced from ... in the body. Unlike conventional genes, they do not ...
... have increasingly relied on the wild and weedy relatives of ... and other traits. But just like all wild plant species, ... decline and extinction due to habitat loss, pollution, and climate ... describe the latest efforts to identify and protect the wild ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Protecting the weedy and wild kin of globally important crops 2